This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Glaucoma Treatment With Food Additives

This study has been terminated.
(The trial was terminated due to investigator's decision)
Information provided by:
Future Products Management Identifier:
First received: September 12, 2005
Last updated: March 10, 2009
Last verified: March 2009
The purpose of this study is to determine if certain food additives are effective in the treatment of glaucoma, improving and reversing the progress of the disease.

Condition Intervention Phase
Glaucomatous Neuropathy Drug: Vitamins, minerals and medical herbs Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Treatment of Glaucomatous Neuropathy With Food Additives

Resource links provided by NLM:

Further study details as provided by Future Products Management:

Primary Outcome Measures:
  • Improvement in vision field (Protocol24) in a Humphrey's instrument. Scoring according to the Agis study

Estimated Enrollment: 25
Study Start Date: September 2005
Study Completion Date: October 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Detailed Description:
Glaucomatous neuropathy is a condition that worsens with time causing atrophy of the optic nerve and narrowing of the visual field which may culminate in blindness. The treatment tested in the trial employs certain food additives intended to reverse this pathology.

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable open angle glaucoma - with equilibrated eye internal pressure
  • Above the age of 50 years and have severe damage that does not progress to the vision field in the upper and lower half. Scoring of the vision field will be made according to the Agis study instructions.

Exclusion Criteria:

  • Eye diseases excluding past cataract operation
  • Allergy to one of the components in the preparation
  • Deterioration in the vision field in the last year
  • Kidney diseases, gastrointestinal (G.I.) tract, liver diseases, coagulation problems and thyroid diseases
  • Persons who take steroids
  • Diabetics or unbalanced hyperglycemia
  • Autoimmune diseases
  • Hypertension (not responding to treatment)
  • Psychiatric treatment with drugs, psychiatric pathologies
  • Pregnancy
  • Ability to take more than 3 pills per day regularly
  • Smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00196677

Sheba Medical Center
Tel Hashomer, Israel, 52621
Sponsors and Collaborators
Future Products Management
Study Director: Meir Gorban, MD Future Products Management
Principal Investigator: Hani Levkovitch-Verbin, MD Sheba Medical Center
  More Information

Responsible Party: Dr. Meir Gorban, Future Products Management Identifier: NCT00196677     History of Changes
Other Study ID Numbers: g88
Study First Received: September 12, 2005
Last Updated: March 10, 2009 processed this record on August 18, 2017